ࡱ> Root EntryRoot Entryve8)FileHeadermDocInfoZHwpSummaryInformation.R BodyText pS8T8PrvImage  PrvTextDocOptions ve8ve8Scripts ve8ve8JScriptVersion t DefaultJScriptq_LinkDocu  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQSTUVWXY[\]^_`abcdefghijklnoprsvwxyz{|}8] <\><Systematic approaches to identify novel therapeutic strategies to overcome the resistance of EGFR targeted drugs > <\Դ><Activation of the EGF receptor (EGFR) kinase, a member of the ErbB family of receptor tyrosine kinases, plays a central role in cancer pathogenesis. Notably, somatic mutations within the kinase domain of the EGFR gene occur in lung adenocarcinoma in about 8% of patients from Europe and North America and 30% of patients from East Asia, with the L858R mutation in exon 21 and exon 19 in frame-deletions accounting for 88% of these mutations. Inhibition of the activated EGFR with either tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib or anti-EGFR antibodies such as cetuximab, is an effective modality of treatment for multiple human cancers caused by oncogenic EGFR genomics alterations. Despite the dramatic radiologic response observed with these drugs, almost all patients inevitably become resistant less than a year after initial treatment, mediated by seve>GIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`iTݵtʥ-[uẃ+^̸1Ð#KL˘p-1O@ӣKYiԫM^6Тefl ۸k;vݠv^mmvLm Kaꌾ#o>!Ƌ{M^yjFkuuQ~*1u rםnQEW!W(e&$h"b1x[X\seh`usI#IBF(VuId$I6eD[VG[9YvkjfFt8Ng oɑ I$2y8ۓuiP_B$SfD}>Yyxg٦E9 v}7qfǜH¶7b쯹Ff|v&Wzޛ@\jz6i5&klnǮE$EgLQd)0Sޘn2:lA< o1j#G(vʫ(JF$J:3 l6$Q;{pY=jÊny7&-7"[{/,:5cm缶:.Ȯҹky&ڬ&GG|nZ7)&+d26ofbv_KIJZ/J納T ;Uתڝňn+Alk+sdzsr̿CHƯf}١]-w]M1X0XJ~B;Uur|DViQEnG N] e:uf O_I"O\ЗjD&vpx#,+2ּ⒑"ᾱxڰվ,=Ұ¢ьbUꟴ*4jK"Tܾ%-i7PPԂѵǛ.?Ҧɰ)ɪWt]&$R*Fk4b E׶gnEв]3C/yA[*Cn٬j aוvwuvrXUͣIJR>Շ/[JǴض"$ƶc?5墌s0HUϞ;)--AT/oΆg縳ۅl*Ѓ4("+ӥ0=3챷1δ!H#3=P2UͱԴ'۲ԴڷɺPԴ,ճ%<8ImZ˲3>Ǻ)mrnD7}8vv'=rN*3m%8\4e+o䭮9]k9˹nT|8ąru'}q^zP:FY`Sm.xq.Cz;)}Cso#w6ywvB7sִnww}. ӿ^0~O/;ϝ~qËӖw{.vkNw;8_OguC-o8ȋCXJus<W7{>'ugp{9r=vue.}[G]| ?O>)~Po18Xx ؀8Xx؁;`a``a`0x  t  ajou2010D 2 10| ”| $ 2:36:28jeong-9, 6, 1, 6843 WIN32LEWindowsSection0~ _Unknown_Version@m @pS8@V;oADFv$B% A$Rњ@e )R@½KJ (`v.;|K1ʜfo}ޕ)W 4H{}s<<\$J^LQCüb6n6l0`^ez>ޑİ0ä-*1֭w;(7Pɤ2"<0<׬pYioZg#+_W:6ejamn5xjhD u@sjwg(7ʉPjq QIP!D pa8]};QJH%ªdԺ*9&=EM ~W\>Pj5L퇌W ɴ#}ҫsU-VKÚJ+72Yn'o+N ZZ- i7+N-HeHz5Yj[]VLA`j -\9(`lABE؇c`WCH7K9v;9z"w`xwgqr`K|&l:,fdL|>#st!#3כ,0>},dCoW -kQǿ26 .ڟ{\DEրś-Dx'׈bQi j(z{vcw݃Cvcf֊ RBVFuG|"R)@6Vl̡:*(&kʹ,]pE,I' M'"/%($J)PR6NIT ;d%9 v:lI;$7Φ@N@~bvcCQ9:.s SQ OX^gK5zULݞ3/`̨~wtX0!I*ML5;Ò oF02 Y} 70ܧ'Uug<1z=BABj~aCQ{lRctIV;lXIpq;;_lNyγ/^WOL~ы"<\Y5W2d^U <46*6*GiQQfT{q_"X] {LHWP Document Fileu@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#cd߈reatment for multiple human cancers caused by oncogenic EGFR genomics alterations. Despite the dramatic radiologic response observed with these drugs, almost all patients inevitably become resistant less than a year after initial treatment, mediated by seve>W1lU['g )%Av I{gCwM$" dAa! $(AJ2EQ.Eyy[m;oY3KDQѿ.Ea|E$,ޗn>r.z#X-'w:rͻz)T#{Dw/9,~mλgǩ} ws}J/H5+!YaFT;'4Ty|_u9KD;GkW_v9aqh 1@tNi9SрbR|SH5c}{c<然CLCQbSme:;q m2 aM8OFoF<{Ė߇lӠz\VtM^)}?l̸>,qݝ8ǬĎǕ)Ѭ9$<y4-PyMY~Oc2R?7/+]݁th*'!f}мExMo =]%P[Ϫ{PCXUuQaţFW^-jV?C*Ɉ!xY7ʤx -kHէ%zX+8xpNR`r45z1t%`9g2~ 5yKh "iG7:5E00Ku4ӸRu~E4 R^^5[J~Kb&aY&[Pa.f? AQ==o $C@Dfvv^g|^f939s39tgf_u1ScV/WchD~f֣ƼAY&ޤb^uV5-jOGԘԘln1qؾ՘߰ 1ng"j-byGj/+1{ ՘5[OnnI7vC&h(fI?eo&$&{|.}j.36WO;mtuNGFe6RnɢS!.Q4L4Q}E)CpZ' b'ɲSW/ 0cwo2U| 8|2~n0;?rRيU(d!J'lIyx diV#-1MLsL[ !J< cݮ/M h,e IV,Fą+ ."2l>ϱ㱫D1ٛZĭY*C*Zܭ&7< AbzQnHF@<~{򘜙#`ԈhF` eɸAkbbBa>/N@ -Y ZY[eq(/b>㳦߫0భ屹|⸳